- Home
- PSNL vs VSTM Comparison
PSNL vs VSTM Comparison
Compare PSNL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | VSTM |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 723.8M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PSNL | VSTM |
|---|---|---|
| Price | $8.52 | $7.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $10.71 | ★ $13.38 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,103,000.00 | $13,379,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | $20.33 | $271.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.79 |
| 52 Week Low | $2.83 | $3.46 |
| 52 Week High | $11.40 | $11.25 |
Technical Indicators
Market Signals| Indicator | PSNL | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 33.40 |
| Support Level | $7.68 | $9.13 |
| Resistance Level | $9.85 | $9.91 |
| Average True Range (ATR) | 0.59 | 0.62 |
| MACD | -0.23 | -0.32 |
| Stochastic Oscillator | 30.67 | 6.43 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.